Press Releases Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-03 pm EDT			5-day change	1st Jan Change
49.87 ^USD	+2.72%		+3.25%	-40.27%

01:42pm	B. Riley Cuts Price Target on Cytokinetics to $92 From $122, Maintains Buy Rating	MT
Jun. 03	Cytokinetics Insider Sold Shares Worth $635,978, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cytokinetics to Participate in June Investor Conferences	May. 29	AQ
Cytokinetics Announces Closing of Public Offering of Common Stock	May. 28	AQ
Cytokinetics Announces Pricing of Public Offering of Common Stock	May. 22	AQ
Cytokinetics Announces Proposed Public Offering of Common Stock	May. 22	AQ
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline	May. 22	AQ
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology	May. 17	AQ
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024	May. 15	AQ
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress	May. 13	AQ
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine	May. 13	AQ
Cytokinetics: Q1 Earnings Snapshot	May. 08	AQ
Cytokinetics Reports First Quarter 2024 Financial Results	May. 08	AQ
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy	May. 08	AQ
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586	May. 08	AQ
Cytokinetics to Hold Annual Meeting of Stockholders	May. 07	AQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 02	AQ
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress	Apr. 29	AQ
Cytokinetics to Announce First Quarter Results on May 8, 2024	Apr. 24	AQ
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress	Apr. 10	AQ
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session	Apr. 05	AQ
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Press Releases

Filters